<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053390</url>
  </required_header>
  <id_info>
    <org_study_id>xh2009-35</org_study_id>
    <nct_id>NCT01053390</nct_id>
  </id_info>
  <brief_title>New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma</brief_title>
  <official_title>A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The first clinical college of harbin medical university</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The people's hospital of Heilongjiang province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Air Force Military Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qinghai People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Qinghai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Kunming</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The first people's hospital of Guiyang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Kunming Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective Primary:&#xD;
&#xD;
      Determine the objective response rate in patients with advanced gallbladder treated with new&#xD;
      Chemotherapy regimen&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      Determine time to progression-free survival and overall survival of patients treated with&#xD;
      this regimen.&#xD;
&#xD;
      Determine quality of life of patients treated with this regimen. Determine the toxicity of&#xD;
      new chemotherapy regimen&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Treatment, Randomized, Open Label, controlled,Multicenter Group Assignment,&#xD;
      Safety/Efficacy Study&#xD;
&#xD;
      Chemotherapy regimen:&#xD;
&#xD;
      Group A: Conventional chemotherapy regimen Group B: New chemotherapy regimen: conventional&#xD;
      regimen plus SST（somatostatin） Cycles repeat every 4 weeks and 6 cycles in total&#xD;
&#xD;
      Patients: A total of 260 patients (130 per group) will be accrued for this study.&#xD;
&#xD;
      Patients distribution:&#xD;
&#xD;
      10patients per center are enrolled in the study and 30 centers (hospitals) in total which&#xD;
      meet the total number of patients in trial.&#xD;
&#xD;
      Clinical Outcome Assessments:&#xD;
&#xD;
      Primary: the objective response rate (response evaluation criteria in solid tumors ,RECIST&#xD;
      criteria) Secondary: progression-free survival, overall survival, quality of life，the adverse&#xD;
      event&#xD;
&#xD;
      Safety Assessments:&#xD;
&#xD;
      Physical exam, laboratory test, probably occurred adverse event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Response Evaluation Criteria in Solid Tumors, RECIST,2009 ), CR(complete response) and PR(partial response)</measure>
    <time_frame>6 month after first treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A: KPS (karnofsky performance score) B:Laboratory tests: Reexamination of CA19-9（Carbohydrate Antigen 19-9）、 CEA（ carcinoembryonic antigen）, especially for those which are abnormal prior to chemotherapy</measure>
    <time_frame>6 month after first treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Gallbladder Neoplasms</condition>
  <arm_group>
    <arm_group_label>epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Somatotatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional chemotherapy regimen plus somatostatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h</description>
    <arm_group_label>Somatotatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）</intervention_name>
    <arm_group_label>Somatotatin</arm_group_label>
    <arm_group_label>epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with unresectable locally advanced disease or unresectable local recurrence,&#xD;
             including:&#xD;
&#xD;
               -  Patients with unresectable advanced gallbladder cancer （≥ Nevin staging IV or&#xD;
                  TNM（ tumor node metastasis） classification）&#xD;
&#xD;
               -  Patients with complication who have no indication for surgery&#xD;
&#xD;
               -  Patients with unresectable local recurrence lesions&#xD;
&#xD;
          2. Age between 18-75, no gender-based constraints&#xD;
&#xD;
          3. Estimated life expectancy ≥12 weeks&#xD;
&#xD;
          4. KPS（Karnofsky performance status ）≥60&#xD;
&#xD;
          5. Each patient gave written informed consent&#xD;
&#xD;
          6. &lt; 2 previous chemotherapy regimes&#xD;
&#xD;
          7. No chemotherapy done in the last 4 weeks&#xD;
&#xD;
          8. Laboratory test criteria:Haemoglobin ≥ 10g/dl, white blood cell count &gt; 3,000/mm3&#xD;
             ;Platelet &gt;100,000/mm3 Total bilirubin &lt;5.0mg/dl ALT（alanine transaminase）、&#xD;
             AST（aspartate aminotransferase)≤ 2.5 times upper limit of normal BUN（blood urea&#xD;
             nitrogen）≤ 2 times upper limit of normal; serum creatinine &lt;1.5mg/dl: creatinine&#xD;
             clearance rate &lt; 60 ml/min&#xD;
&#xD;
          9. Patients are required to have histologically confirmed diagnosis via puncture based at&#xD;
             least on computed tomography (CT) or ultrasound&#xD;
&#xD;
         10. Jaundice should be reduced to standard level before chemotherapy (Total bilirubin &lt;5.0&#xD;
             mg/dl)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with extensive metastasis and generally poor condition who can not tolerate&#xD;
             chemotherapy&#xD;
&#xD;
          2. Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          3. Patients with other clinically significant laboratory abnormalities, uncontrolled&#xD;
             infection, concurrent severe medical problems unrelated to malignancy&#xD;
&#xD;
          4. Patients who had a history of previous carcinoma in the last 5 years.&#xD;
&#xD;
          5. Patients who are allergic to somatostatin or fluorouracil&#xD;
&#xD;
          6. Patients who refuse chemotherapy, or to sign the informed consent and chemotherapy&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-wei Quan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xinhua hospital affiliated shanghai jiaotong university school of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xinhua hospital affiliated shanghai jiaotong</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.btcrc.com.cn</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-wei Quan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gallbladder neoplasmas</keyword>
  <keyword>Gallbladder Neoplasms,Advanced Stage,Chemotherapy,Somatostatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

